Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02871648 · ClinicalTrials.gov registry record · Phase 1
The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production
A Phase 1 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT02871648 is a Phase 1 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 23 participants.
The verdict
NCT02871648, a Phase 1 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this research protocol is to determine if the same effects are observed in vivo in humans using a similar approach. Demonstrating that mineralocorticoid acts on zona glomerulosa cells to regulate aldosterone production in a short feedback loop would provide important insight into hormone regulation, and explain variability in pathophysiologic states such as hypertension and cardiovascular diseases.
Interventions
- DRUG Placebo
- DRUG Eplerenone
- DRUG Fludrocortisone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2016-01 |
| Est. Completion | 2019-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02871648
The ClinicalTrials.gov registry entry for NCT02871648 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02871648 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02871648 about?
NCT02871648 is a clinical study titled "The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production". The purpose of this research protocol is to determine if the same effects are observed in vivo in humans using a similar approach. Demonstrating that mineralocorticoid acts on zona glomerulosa cells to regulate aldosterone production in a short feedback loop would provide important insight into horm...
What is the current status of trial NCT02871648?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2016-01. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02871648?
The interventions under investigation include: Placebo (DRUG), Eplerenone (DRUG), Fludrocortisone (DRUG).
Who is sponsoring clinical trial NCT02871648?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.